Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase i clinical trial

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 765-775

  Welsh, J L ^a   Wagner, B A ^a   Van'T Erve, T J ^a   Zehr, P S ^b   Berg, D J ^a,b   Halfdanarson, T R ^a,b   Yee, N S ^c   Bodeker, K L ^a   Du, J ^a   Roberts II, L J ^d   Drisko, J ^e   Levine, M ^f   Buettner, G R ^a,b   Cullen, J J ^a,b,g  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ascorbic acid; Clinical trial; Drug toxicity; Gemcitabine; Pancreatic neoplasm; Phase 1

Indexed keywords

ASCORBIC ACID; GEMCITABINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTIOXIDANT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG OXIDATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAIR DISEASE; HEART ARRHYTHMIA; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; OXIDATION REDUCTION REACTION; PAIN; PANCREAS CANCER; PANCREAS METASTASIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VOLUME; WEIGHT REDUCTION; XEROSTOMIA; ADENOCARCINOMA; BLOOD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PANCREAS TUMOR; PATIENT COMPLIANCE; PATIENT SAFETY; SENTINEL LYMPH NODE BIOPSY;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; ASCORBIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATIENT COMPLIANCE; PATIENT SAFETY; SENTINEL LYMPH NODE BIOPSY;

MLCS; MLOWN;

EID: 84875857303     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2070-8     Document Type: Article

References (26)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29
3. Winstead ER (2009) Pancreatic cancer report urges changes in clinical trials. NCI Cancer Bulletin
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 15(6):2403-2413 (Pubitemid 27251144)
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825
6. Buettner GR, Jurkiewicz BA (1996) Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145(5):532-541 (Pubitemid 26127160)
7. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR et al (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102(38):13604-13609 (Pubitemid 41420895)
8. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E et al (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104(21):8749-8754 (Pubitemid 47175383)
9. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH et al (2010) Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16(2):509-520
10. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M et al (2011) Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50(11):1610-1619
11. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR et al (1996) Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93(8):3704-3709 (Pubitemid 26125678)
12. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A et al (2004) Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140(7):533-537
13. Levine M, Padayatty SJ, Espey MG, Vitamin C (2011) a concentration- function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2(2):78-88
14. Vislisel JM, Schafer FQ, Buettner GR (2007) A simple and sensitive assay for ascorbate using a plate reader. Anal Biochem 365(1):31-39 (Pubitemid 46617469)
15. Venkataraman S, Martin SM, Schafer FQ, Buettner GR (2000) Detailed methods for the quantification of nitric oxide in aqueous solutions using either an oxygen monitor or EPR. Free Radic Biol Med 29(6):580-585
16. Buettner GR, Kiminyo KP (1992) Optimal EPR detection of weak nitroxide spin adduct and ascorbyl free radical signals. J Biochem Biophys Methods 24(1-2):147-151
17. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87(23):9383-9387 (Pubitemid 120030630)
18. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE et al (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38(6):698-710 (Pubitemid 40249740)
19. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN et al (2005) Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med 38(6):711-718 (Pubitemid 40249741)
20. Park HJ, Mah E, Bruno RS (2010) Validation of high-performance liquid chromatography-boron-doped diamond detection for assessing hepatic glutathione redox status. Anal Biochem 407(2):151-159
21. Jones DP, Liang Y (2009) Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med 47(10):1329-1338
22. Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30(11):1191-1212 (Pubitemid 32463931)
23. Buettner GR, Jurkiewicz BA (1993) Ascorbate free radical as a marker of oxidative stress: an EPR study. Free Radic Biol Med 14(1):49-55 (Pubitemid 23024257)
24. Buettner GR, Wagner BA (2011) Rodgers VG. An approach to understand the role of reactive species in defining the cellular redox environment, Cell Biochem Biophys Quant Redox Biol
25. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K et al (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19(11):1969-1974
26. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ et al (2012) Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE 7(1):e29794